Antabio is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments targeting drug-resistant infections caused by WHO and CDC critical priority pathogens. Guided by scientific excellence and a clear mission, Antabio’s mission is to deliver life-saving therapies that combat antimicrobial resistance (AMR) and help preserve the effectiveness of antibiotics for future generations. Antabio’s lead program, MEM-ANT3310, is a next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination currently in Phase 1 clinical development. Designed to treat severe hospital infections caused by multidrug-resistant Gram-negative bacteria, MEM-ANT3310 represents a major step forward in addressing one of the most urgent public health challenges of our time.
Looking for a particular ANTABIO employee's phone or email?
ANTABIO Questions
The ANTABIO annual revenue was $6.1 million in 2026.
Aurélien Chollet is the Vice President Finance and Operations of ANTABIO.
15 people are employed at ANTABIO.
ANTABIO is based in Labege, Occitania.
The NAICS codes for ANTABIO are [325, 32541, 3254, 32].
The SIC codes for ANTABIO are [28, 283].
Top ANTABIO Employees
-
Aurélien Chollet
Vice President Finance and Operations at ANTABIO
Toulouse, Occitanie, FR2 -
Marc Lemonnier
Founding CEO at ANTABIO
Occitanie, France2 -
Justine Dao
Clinical Pharmacologist at ANTABIO
Vincennes, FR1 -
Carine Danaire
Executive Assistant and HR Manager at ANTABIO
Toulouse, Occitanie, FR1 -
Laura Fabre
Clinical Project Manager at ANTABIO
Toulouse, Occitanie, FR1 -
33
Related Companies
